RHYTHM PHARMACEUTICALS, INC. (RYTM)
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
📈 **POSITIVE** • Low confidence analysis (55%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (77%) **Content type:** Clinical